Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Catheter ablation in ventricular tachycardia].

M Borggrefe1, H Hindrichs, W Haferkamp

  • 1Medizinische Klinik und Poliklinik, Innere Medizin C, Westfälische Wilhelms-Universität Münster.

Herz
|April 1, 1990
PubMed
Summary

Pharmacologic treatment for ventricular tachycardia (VT) is often ineffective. Catheter ablation offers an alternative by selectively destroying the heart tissue responsible for initiating VT, providing a definitive treatment option.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety of Antiplatelet Pretreatment in Non-ST-segment Elevation Acute Coronary Syndrome.

European cardiology·2023
Same author

Oral Presentation Award Winner: LDL-C Reduction in Diabetic Patients after Percutaneous Coronary Intervention: Is There any Difference with Non-diabetic?

European cardiology·2023
Same author

Oral Presentation Award Winner: Appropriateness of Antiplatelet Pretreatment in Non-ST-segment Elevation Acute Coronary Syndrome: Differences Between Unstable Angina and Acute Myocardial Infarction.

European cardiology·2023
Same author

Prescription of Sacubitril/Valsartan in Patients with Heart Failure and Reduced Ejection Fraction Attending an Outpatient Heart Failure Clinic.

European cardiology·2020
Same author

Tolerability Profile and Discontinuation Causes of Sacubitril/Valsartan Treatment in 'Real-life' Patients with Heart Failure and Reduced Ejection Fraction.

European cardiology·2020
Same author

Antiarrhythmic drugs-clinical use and clinical decision making: a consensus document from EHRA and ESC WG on Cardiovascular Pharmacology endorsed by HRS, APHRS, and ISCP-Authors' reply.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2018

Area of Science:

  • Cardiology
  • Electrophysiology
  • Medical Devices

Context:

  • Pharmacologic management of ventricular tachycardia (VT) has limited efficacy, affecting only 20-30% of patients.
  • Alternative therapies include antitachycardia stimulation, implantable defibrillators, and catheter ablation.
  • Catheter ablation aims to selectively destroy cardiac structures causing VT initiation.

Purpose:

  • To describe the principles and techniques of catheter ablation for ventricular tachycardia.
  • To detail the process of catheter mapping and ablation for VT.
  • To present catheter ablation as a definitive treatment for VT.

Summary:

  • Catheter ablation, initially discovered serendipitously, targets the endocardial origin of VT, often in myocardial infarction scar regions.

Related Experiment Videos

  • Endocavity catheter mapping identifies the earliest activation site during sinus rhythm and VT, guiding pace-mapping.
  • Ablation involves delivering electrical shocks via a catheter to destroy the VT circuit, with reassessment after each shock.

    • Impact:

    • Catheter ablation provides a definitive treatment option for ventricular tachycardia when pharmacologic therapy fails.
    • This technique allows for the selective destruction of arrhythmogenic substrates.
    • Advances in mapping and ablation techniques improve outcomes for patients with refractory VT.